Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF

NCT02501811 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.

NCT NCT02501811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02501811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF
Lead sponsor
The University of Texas Health Science Center, Houston
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
July 22, 2020
Enrollment
125 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic cardiomyopathy